Novartis (Sweden)-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2015

  1. Pharmacometrics Markup Language (PharmML): Opening new perspectives for model exchange in drug development

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 4, Núm. 6, pp. 316-319

2014

  1. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 3, Núm. 5

2010

  1. Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: A conceptual framework

    Basic and Clinical Pharmacology and Toxicology

  2. Modelling the genesis and treatment of cancer: The potential role of physiologically based pharmacodynamics

    European Journal of Cancer, Vol. 46, Núm. 1, pp. 21-32

2004

  1. Modelling and simulation in the development and use of anti-cancer agents: An underused tool?

    Journal of Pharmacokinetics and Pharmacodynamics